More News
Want to Read Locked Articles?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Viatris, Ocuphire Announce US Launch of Ryzumvi to Reverse Pupil Dilation
Author: Jennie Crabbe
Viatris and Ocuphire Pharma announced April 1 the US launch of Ryzumvi (phentolamine ophthalmic solution) 0.75% for the reversal of pharmacologically induced mydriasis. The US FDA approved Ryzumvi in September 2023. It is the only FDA-approved eye drop to reverse dilation commercially available in the US. Ryzumvi is a preservative-free eye drop formulation designed to modulate pupil size by blocking the α1 receptors found only on the iris dilator muscle, without affecting the ciliary muscle. ...
Purchasing one of the following products will open up access to this article's content, which is also available in each comprehensive report/subscription.
Recommended Products
This website uses cookies to ensure you get the best experience. By continuing to use our website, you consent to our use of cookies.